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ABSTRACT
Objectives: To develop and validate a clinical risk
score to identify patients at risk of chronic obstructive
pulmonary disease (COPD) using clinical factors
routinely recorded in primary care.
Design: Case–control study of patients containing one
incident COPD case to two controls matched on age,
sex and general practice. Candidate risk factors were
included in a conditional logistic regression model to
produce a clinical score. Accuracy of the score was
estimated on a separate external validation sample
derived from 20 purposively selected practices.
Setting: UK general practices enrolled in the Clinical
Practice Research Datalink (1 January 2000 to 31
March 2006).
Participants: Development sample included 340
practices containing 15 159 newly diagnosed COPD
cases and 28 296 controls (mean age 70 years, 52%
male). Validation sample included 2259 cases and
4196 controls (mean age 70 years, 50% male).
Main outcome measures: Area under the receiver
operator characteristic curve (c statistic), sensitivity and
specificity in the validation practices.
Results: The model included four variables including
smoking status, history of asthma, and lower
respiratory tract infections and prescription of
salbutamol in the previous 3 years. It had a high
average c statistic of 0.85 (95% CI 0.83 to 0.86) and
yielded a sensitivity of 63.2% (95% CI 63.1 to 63.3)
and specificity 87.4% (95% CI 87.3 to 87.5).
Conclusions: Risk factors associated with COPD and
routinely recorded in primary care have been used to
develop and externally validate a new COPD risk
score. This could be used to target patients for case
finding.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is the third leading cause of mortal-
ity.1 However, population studies suggest that
50–80% of the disease burden remains undiag-
nosed.2 3 A recent analysis of UK primary
healthcare records showed that opportunities
to diagnose COPD are frequently missed with
up to 85% of patients presenting within
5 years of their diagnosis with indicative symp-
toms and clinical events.4 There is now a drive
to identify such patients in order to instigate
early management and reduce disease pro-
gression.5 6 A variety of screening tools have
been proposed and evaluated including
symptom-based questionnaires,7 and use of
handheld8 and diagnostic spirometry.9
However, mass screening is likely to be costly
and a more targeted approach is required to
improve their efﬁciency.
Several clinical prediction models have
been developed to identify individuals at risk
of undiagnosed COPD. These include two
developed in the USA using administrative
claims data,10 11 one in Denmark using
primary and secondary care data,12 and most
recently in Scotland using routine primary
healthcare data.13 The ﬁrst three models are
unlikely to be implementable in a UK or
similar primary care setting because of differ-
ences in healthcare structures as well as the
included predictor variables, many of which
are not routinely recorded. The Scottish
model while likely to be implementable only
considered a very limited number of poten-
tial risk factors and was not externally
validated.13
KEY MESSAGES
▸ Opportunities to diagnose chronic obstructive
pulmonary disease (COPD) in primary care are
frequently missed.
▸ Data routinely recorded in primary care can be
used to identify patients with undiagnosed
COPD.
▸ We report the development and external valid-
ation of a clinical risk score for COPD in primary
care, providing important information for the
future development of risk prediction models for
COPD that may be used to stratify patients for
case finding.
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We report the development and external validation of
a clinical prediction model that provides a score for
identifying patients at high risk of undiagnosed COPD
in primary care.
METHOD
Study design
Electronic primary care records were available from a
matched case–control data set obtained from the
General Practice Research Database (GPRD; now the
Clinical Practice Research Datalink). Cases with incident
COPD were matched by age, sex and general practice
with controls without COPD (1:2).
Risk score derivation and external validation
Description of dataset
The GPRD is a computerised database of longitudinal
anonymised patient records from a representative
sample of 480 general practices across the UK, covering
approximately 6% of the population.14
Selection of cases and controls
Cases consisted of all patients aged ≥35 years on 1st
April 2006 with a new diagnosis of COPD recorded
between 1 January 2000 and 1 April 2006 (see online
supplementary table S1 for clinical codes). Cases had at
least 3 years of up-to-standard data (ie, data entry
meeting set quality standards) prior to the date of
COPD diagnosis (index date). Controls had no diagnosis
of COPD, were registered on the index date and also
had at least 3 years of up-to-standard data.
Identification of candidate risk factors
Risk factors associated with newly diagnosed COPD were
identiﬁed from published epidemiological studies.
Studies were identiﬁed from Medline, Embase and
Google Scholar using ‘COPD’ (and relevant synonyms)
and ‘risk factor’ as Medical Subject Headings and free
text. From 544 articles we identiﬁed 46 candidate risk
factors that were likely to be routinely recorded in
primary care (see online supplementary table S2). The
ﬁnal list included smoking history, comorbidities
(including asthma, ischaemic heart disease and depres-
sion), lower respiratory tract infections (LRTIs) and
upper respiratory tract infections, respiratory symptoms
(including cough, dyspnoea, wheeze and sputum pro-
duction), systemic symptoms (including unintentional
weight loss, chronic fatigue, and poor sleep), body mass
index and health service use including medication pre-
scriptions (salbutamol, oral prednisolone and antibiotics
for a LRTI) and number of previous primary care
consultations.
Data extraction
Clinical codes for each variable were identiﬁed using the
CPRD medical and product dictionaries and the NHS
Clinical Terminology Browser V.1.04.15 Data on
demographic characteristics, smoking, comorbidities,
respiratory symptoms and health service use were
extracted over the speciﬁed period (see online
supplementary table S2). Data recorded within 60 days
prior to the index date were excluded since a clinical
suspicion of COPD could have inﬂuenced clinical activ-
ity during this period.10 Smoking status closest to the
COPD diagnosis date (or matched time point) was used
to reﬂect likely clinical practice.
Sample size and creation of derivation and validation
data sets
The data set was split into a development and external
validation sample (while preserving matching of cases
and controls) by purposively selecting 20 general prac-
tices that reﬂected the full range of practice and popula-
tion characteristics where the risk score would be
applicable. These practices each had at least 200 indivi-
duals to ensure validation statistics were estimated with
high precision.
Model development
Both the unadjusted and adjusted association between
each factor and COPD were estimated using conditional
logistic regression (to account for matching of cases and
controls). Risk factors were included in the model based
on statistical signiﬁcance (adjusted OR≥1.5 and p value
<0.05) and clinical understanding, with the aim to
achieve a parsimonious and clinically acceptable model.
The ﬁnal model was simpliﬁed by including only four
risk factors that had the highest adjusted ORs and were
most likely to be recorded in a range of primary care
settings.
Missing smoking status was accounted for by including
a missing value category in the regression model.
Patients in primary care often have unknown smoking
status and the model in practice may be applied to such
patients. Missing data for other factors was assumed indi-
cative of their true absence. Risk scores were computed
for each individual by combining the estimated regres-
sion log ORs (β coefﬁcients) from the ﬁnal model with
the individual’s risk factor values.
External validation and model performance
The accuracy of the risk score was evaluated in each of
the 20 validation practices by producing the correspond-
ing receiver operator characteristic (ROC) curve and
estimating the area under it (c statistic). To summarise
the average performance across the 20 practices, the
c statistic estimates were synthesised in a random effects
meta-analysis. We also summarised the heterogeneity in
performance by estimating a 95% interval for the range
of potential c statistics.16
A score threshold to deﬁne ‘high risk’ was selected by
optimising the balance between the sensitivity and posi-
tive predictive value (PPV), assuming a prevalence of
undiagnosed COPD of 5.5% in the general popula-
tion.17 We divided the total number screened by the
2 Haroon S, Adab P, Riley RD, et al. BMJ Open Resp Res 2014;1:e000060. doi:10.1136/bmjresp-2014-000060
Open Access
group.bmj.com on June 22, 2015 - Published by http://bmjopenrespres.bmj.com/Downloaded from 
number of true positives to derive the number-
needed-to-screen (NNS) to detect a single case of
COPD. The number of diagnostic assessments needed
to detect a single case of COPD was estimated as the
reciprocal of the PPV.
RESULTS
Development sample: population characteristics
15 159 newly diagnosed COPD cases and 28 296 controls
from 340 general practices were included in the develop-
ment sample (tables 1 and 2). Mean age was 70 years
and 52% were male. Cases and controls were matched
and therefore identical in age, sex, and socioeconomic
status of registered practice. 27% were current smokers,
25% ex-smokers and 40% had never smoked. A signiﬁ-
cantly higher proportion of cases than controls had a
positive smoking history (77% vs 38%, respectively). All
co-morbidities except hyperlipidaemia and diabetes mel-
litus were more common in cases than in controls. This
was also true for respiratory and systemic symptoms,
including fatigue and poor sleep, as well as health
service use.
Model results
The ﬁnal model included history of smoking, asthma
and salbutamol prescriptions and number of LRTIs in
the previous 3 years (table 3). There was a signiﬁcant
drop in the model ﬁt when removing asthma, salbuta-
mol and LRTIs. The model was used to derive a clinical
score ranging from 0 to 6.5 as shown below table 3. This
had a c statistic in the development sample of 0.85 (95%
CI 0.845 to 0.853). A more comprehensive model that
incorporates additional variables, including symptoms, is
provided in table 4.
External validation sample: population characteristics
A total of 2259 newly diagnosed cases and 4196 controls
from 20 general practices were included in the valid-
ation sample (table 5). The mean age was 70 years, 50%
were men, and 26.6% were current smokers. A greater
proportion of participants in the validation sample than
the development sample were from the lowest socio-
economic quintile (42.4% vs 26.8%, respectively).
External validation: discriminative ability
The ﬁnal risk score had a c statistic of 0.84 (95% CI 0.83
to 0.85) in the validation sample when analysing the
data from all 20 practices combined (ignoring clustering
of patients within practices; ﬁgure 1). The c statistic in
each of the validation practices separately was consist-
ently high (ﬁgure 2) and a random effects meta-analysis
(which takes into account clustering) produced a similar
Table 1 General characteristics of participants in the development sample
Controls (n=28 296) Cases (n=15 159)
Unadjusted OR (95% CI)N (%) N (%)
Mean age (SD) 69.7 (10.8) 69.7 (10.9) –
Males 14 655 (51.8) 7849 (51.8) –
Socioeconomic quintile*
1 5035 (17.8) 2698 (17.8) –
2 4156 (14.7) 2237 (14.8) –
3 5079 (17.9) 2733 (18.0) –
4 6386 (22.6) 3429 (22.6) –
5 7640 (27.0) 4062 (26.8) –
Smoking status†
Never 14 693 (51.9) 2758 (18.2) 1
Former 6013 (21.3) 4671 (30.8) 4.79 (4.49 to 5.10)
Current 4831 (17.1) 6961 (45.9) 8.99 (8.43 to 9.59)
Missing 2759 (9.8) 769 (5.1) 1.37 (1.23 to 1.51)
BMI†
<18.5 5810 (20.5) 2917 (19.2) 0.80 (0.76 to 0.85)
18.5–25 8651 (30.6) 5232 (34.5) 1
25–30 9299 (32.9) 4475 (29.5) 0.79 (0.75 to 0.83)
>30 4536 (16.0) 2535 (16.7) 0.93 (0.87 to 0.98)
Unadjusted OR for association with COPD.
Unadjusted ORs for age, sex and socioeconomic status of general practice were not estimated as cases and controls were matched on these
variables.
*1=least deprived.
2
3
4
5=most deprived.
Based on Index of Multiple Deprivation score of general practice electoral ward.
†Closest to diagnosis.
BMI, body mass index; COPD, chronic obstructive pulmonary disease.
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Table 2 Comorbidities, symptoms, and healthcare use of participants in the development sample
Controls (n=28 296) Cases (n=15 159) Unadjusted
OR (95% CI)N (%) N (%)
Comorbidities*
Asthma 2438 8.6 5669 37.4 6.61 (6.23 to 7.02)
Ischaemic heart disease 5572 19.7 3560 23.5 1.31 (1.25 to 1.38)
Heart failure 687 2.4 847 5.6 2.50 (2.24 to 2.77)
Stroke 850 3.0 539 3.6 1.23 (1.10 to 1.37)
Hyperlipidaemia 3327 11.8 1660 11.0 0.93 (0.87 to 1.00)
Anaemia 1554 5.5 859 5.7 1.04 (0.95 to 1.14)
Pulmonary embolism 50 0.2 71 0.5 2.72 (1.89 to 3.91)
Deep vein thrombosis 139 0.5 107 0.7 1.44 (1.12 to 1.86)
Atrial fibrillation 980 3.5 690 4.6 1.37 (1.24 to 1.51)
Lung cancer 35 0.1 68 0.4 3.68 (2.45 to 5.55)
Cancer 3805 13.4 2098 13.8 1.05 (0.99 to 1.11)
Depression† 967 3.4 630 4.2 1.24 (1.12 to 1.38)
Anxiety† 2056 7.3 1816 12.0 1.77 (1.65 to 1.90)
Allergic rhinitis 1917 6.8 1152 7.6 1.13 (1.05 to 1.22)
Tuberculosis 421 1.5 365 2.4 1.66 (1.44 to 1.91)
Pulmonary tuberculosis 371 1.3 344 2.3 1.77 (1.52 to 2.06)
Chronic kidney disease 56 0.2 45 0.3 1.69 (1.11 to 2.60)
Helicobacter pylori 188 0.7 139 0.9 1.45 (1.16 to 1.81)
Gastric ulcer 545 1.9 472 3.1 1.63 (1.43 to 1.85)
Gastooesophageal reflux disease 1897 6.7 1229 8.1 1.25 (1.16 to 1.35)
Osteoporosis 713 2.5 569 3.8 1.58 (1.41 to 1.78)
Fractures 3862 13.6 2547 16.8 1.30 (1.23 to 1.38)
Diabetes 2167 7.7 1015 6.7 0.87 (0.81 to 0.94)
Rheumatoid arthritis 462 1.6 369 2.4 1.52 (1.32 to 1.75)
Lower respiratory tract infections†
0 25 128 88.8 9344 61.6 1
1 2205 7.8 2947 19.4 4.02 (3.76 to 4.29)
>1 963 3.4 2868 18.9 9.76 (8.93 to 10.66)
Upper respiratory tract infections†
0 22 355 79.0 10 623 70.1 1
1 3917 13.8 2702 17.8 1.47 (1.39 to 1.56)
>1 2024 7.2 1834 12.1 1.98 (1.85 to 2.13)
Allergy 7614 26.9 5045 33.3 1.40 (1.34 to 1.46)
Symptoms†
Presentations with cough
0 23 470 82.9 8180 54.0 1
1 3072 10.9 3130 20.6 3.14 (2.96 to 3.34)
>1 1754 6.2 3849 25.4 7.12 (6.64 to 7.63)
Presentations with dyspnoea
0 26 789 94.7 11 294 74.5 1
1 1014 3.6 2220 14.6 5.57 (5.12 to 6.06)
>1 493 1.7 1645 10.9 9.01 (8.05 to 10.09)
Wheeze 456 1.6 1860 12.3 8.89 (7.96 to 9.94)
Sputum production 245 0.9 609 4.0 5.32 (4.52 to 6.26)
Weight loss 211 0.7 306 2.0 2.74 (2.30 to 3.28)
Fatigue 1550 5.5 1215 8.0 1.53 (1.42 to 1.66)
Poor sleep 977 3.5 810 5.3 1.59 (1.44 to 1,75)
Health service use†‡
Antibiotic courses
0 18 799 66.4 5150 34.0 1
1 5361 18.9 3313 21.9 2.34 (2.21 to 2.47)
2 2127 7.5 2267 15.0 4.04 (3.76 to 4.34)
>2 2009 7.1 4429 29.2 8.64 (8.07 to 9.25)
Salbutamol 2492 8.8 7723 50.9 11.5 (10.8 to 12.2)
Prednisolone 1800 6.4 4358 28.7 6.17 (5.78 to 6.58)
GP consultations
<5 5162 18.2 1156 7.6 1
5–10 4618 16.3 1734 11.4 1.81 (1.66 to 1.98)
10–20 7677 27.1 3745 24.7 2.55 (2.36 to 2.77)
20–40 7610 26.9 5136 33.9 3.99 (3.68 to 4.32)
>40 3229 11.4 3388 22.3 6.91 (6.31 to 7.57)
Hospital referrals 703 2.5 687 4.5 2.08 (1.85 to 2.34)
Unadjusted OR for association with COPD.
*Ever previously diagnosed.
†Within 3 years of COPD diagnosis or equivalent matched time point for controls.
COPD, chronic obstructive pulmonary disease; GP, general practitioner.
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summary c statistic of 0.85 (95% CI 0.83 to 0.86), with a
95% prediction interval of 0.80 to 0.90. The more com-
prehensive score had a marginally higher c statistic
(0.87, 95% CI 0.86 to 0.87).
Table 6 summarises the performance of the ﬁnal score
across a range of thresholds in the validation sample.
A score threshold ≥2.5 yielded a sensitivity of 63.2%
(95% CI 63.1% to 63.3%) and speciﬁcity 87.4% (95%
CI 87.3% to 87.5%). Assuming a 5.5% prevalence of
undiagnosed COPD,17 the score at our suggested thresh-
old would have a PPV of 22.6%, NPV of 97.6%, and an
overall screening yield of 3.5% when applied to patients
over the age of 35 years. At this threshold the score
would need to be applied to 29 patients, 5 of whom
would require a clinical assessment, to identify one with
COPD (ﬁgure 3).
DISCUSSION
Principal findings
We have developed and validated a clinical prediction
model for identifying patients at high risk of COPD in
primary care. Our clinical score incorporates smoking
status, previous diagnosis of asthma and LRTIs, and pre-
scriptions for salbutamol. The score showed good dis-
crimination characteristics in the external validation
population and our choice of optimal cut point yielded
a relatively high sensitivity and speciﬁcity. It can
potentially detect about three out of every ﬁve patients
with undiagnosed COPD while also being able to effect-
ively rule out patients at low risk of disease. The score
threshold, however, can be altered to either maximise
sensitivity or speciﬁcity.
This builds on our previous published model (based
on data from the Health Survey for England) which
would require 19 patients to actively undertake a screen-
ing process (19 questionnaire responses and 7 clinical
assessments) to identify one individual with COPD.17
Our new clinical score, where we use routine data from
primary care records, would signiﬁcantly improve the
efﬁciency of this process.
Comparison with existing literature
The ﬁrst published risk model to identify patients with
undiagnosed COPD was based on managed (predomin-
antly secondary) care administrative claims data in the
USA.18 Using a case–control design, 19 health service
utilisation characteristics were included, many of which
are unlikely to be routinely recorded in primary care. In
contrast we developed a more parsimonious model that
uses routinely data recorded in primary care.
Furthermore our study population had more complete
data on smoking history. A further US model was devel-
oped using outpatient pharmacy data.11 This incorpo-
rated respiratory and cardiovascular medications and
antibiotics, and had a sensitivity of 60.6% and speciﬁcity
of 70.5% when externally validated. Our risk score simi-
larly included prior prescription of salbutamol as an
important predictor. However, the ROC curve and c stat-
istic for both US models were not reported, which
makes it impossible to evaluate their discriminatory
accuracy.
In Denmark Smidth et al12 used administrative data on
hospital admissions for lung disorders, respiratory pre-
scriptions and lung function tests to develop a model to
identify COPD. This had a much lower sensitivity (29.7–
44.8%) but higher speciﬁcity (98.9%) than the score we
developed. While it had a high PPV in the Dutch popu-
lation (65.0–72.9%; based on an overall COPD preva-
lence of 9%), it would be difﬁcult to administer in a UK
or similar primary care setting where primary and sec-
ondary care data are currently poorly linked. This model
also relies on prior diagnoses of emphysema and
chronic bronchitis at hospital admissions and would
miss a signiﬁcant number of patients due to the low sen-
sitivity and high proportion of false negative results.
Kotz et al13 recently developed and internally validated a
COPD risk model using routine longitudinal data from
primary care in Scotland, including a very large
(n=480 903 in the development cohort) and relatively
young population (mean age 55.6 years). Their model
demonstrated similar discrimination characteristics to our
own (c statistic 0.85 (95% CI 0.84 to 0.85) in women and
0.83 (95% CI 0.83 to 0.84) in men), with good calibration.
However, this has only been internally validated since the
study population was randomly split into derivation and
Table 3 Adjusted ORs and regression coefficients (β) for
risk factors included in the final risk model
OR* (95% CI) β (95% CI)
Smoking status
Never 1 0
Former 4.72 (4.35 to 5.12) 1.55 (1.47 to 1.63)
Current 11.7 (10.7 to 12.7) 2.46 (2.37 to 2.54)
Missing 2.44 (2.16 to 2.76) 0.89 (0.77 to 1.02)
Asthma 2.11 (1.93 to 2.31) 0.75 (0.66 to 0.84)
LRTI†
0 1 0
1 2.57 (2.36 to 2.81) 0.94 (0.86 to 1.03)
>1 4.29 (3.83 to 4.80) 1.46 (1.34 to 1.57)
Salbutamol† 6.91 (6.33 to 7.55) 1.93 (1.85 to 2.02)
As this model was developed using case-control data, the intercept
term is not applicable and has therefore not been presented.
*Estimated using a multivariable conditional logistic regression
model.
†Within 3 years of COPD diagnosis or equivalent matched time
point for controls.
Risk score=(former smoker×1.55)+(current smoker×2.46)
+(unknown smoking status×0.89)+(asthma×0.75)+(1 episode of
LRTI×0.94)+(>1 episode of LRTI×1.46)+(salbutamol×1.93).
NB. Each variable can either take the value 0 (not present) or 1
(present).
For example, A former smoker with a history of asthma who
presented with more than one lower respiratory tract infection in the
past 3 years, and received salbutamol in the past 3 years would
have the following risk score:
(1×1.55)+(0×2.46)+(0×0.89)+((1×0.75)+(0×0.94)+(1×1.46)
+(1×1.93)=5.69.
COPD, chronic obstructive pulmonary disease; LRTI, lower
respiratory tract infection.
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validation samples. Furthermore only a very limited range
of risk factors were considered (age, sex, smoking status,
socioeconomic status and history of asthma) and import-
ant predictors such as respiratory infections were not.
They constructed separate models for men and women
since they found an interaction between smoking status
and sex. We also stratiﬁed our model by sex and repeated
our analysis but found the ORs to be broadly similar to
those in the non-stratiﬁed model.
A variety of screening questionnaires have also been
evaluated. For example Price et al7 assessed the accuracy
of a case ﬁnding questionnaire which included items on
respiratory symptoms, smoking, and allergies and showed
good discrimination characteristics. 8 This and other
questionnaire-based tools can only be used in either
face-to-face consultations or distributed by mail or online.
If used in a population with a 5.5% prevalence of undiag-
nosed COPD, 26 patients would need to be screened to
identify one case of COPD. Our model has the advantage
of being applicable in both face-to-face consultations as
well as integrated with clinical information systems and
used at a practice level to identify whole groups of high-
risk patients who could be invited to screening sessions.
With the latter approach, only ﬁve patients would need to
be invited for assessment to identify one case of COPD,
thus improving its efﬁciency ﬁvefold over the use of
current screening questionnaires.
Strengths
We used data from a large primary care population and
explored a wide range of risk factors, focusing on those
routinely recorded in primary care. Both aspects help
Table 4 Adjusted ORs and regression coefficients (β) for variables included in a more comprehensive risk score
OR* (95% CI) β (95% CI)
Smoking status
Never 1 0
Former 4.36 (4.00 to 4.75) 1.47 (1.39 to 1.56)
Current 12.0 (10.97 to 13.12) 2.48 (2.40 to 2.57)
Missing 2.87 (2.52 to 3.26) 1.05 (0.92 to 1.18)
Asthma 1.89 (1.71 to 2.08) 0.64 (0.54 to 0.73)
LRTI†
0 1 0
1 1.81 (1.64 to 1.99) 0.59 (0.49 to 0.69)
>1 2.23 (1.96 to 2.54) 0.80 (0.67 to 0.93)
Presentations with cough†
0 1 0
1 1.42 (1.30 to 1.56) 0.35 (0.26 to 0.44)
>1 1.77 (1.59 to 1.97) 0.57 (0.46 to 0.68)
Presentations with dyspnoea†
0 1 0
1 3.17 (2.82 to 3.57) 1.16 (1.04 to 1.27)
>1 4.53 (3.89 to 5.28) 1.51 (1.36 to 1.66)
Wheeze† 1.86 (1.60 to 2.17) 0.62 (0.47 to 0.77)
Sputum production† 1.49 (1.17 to 1.90) 0.40 (0.16 to 0.64)
Unintended weight loss† 1.75 (1.33 to 2.31) 0.56 (0.29 to 0.84)
Antibiotic courses for a LRTI†
0 1 0
1 1.33 (1.23 to 1.44) 0.29 (0.21 to 0.37)
2 1.53 (1.38 to 1.70) 0.43 (0.32 to 0.53)
>2 1.80 (1.62 to 2.01) 0.59 (0.48 to 0.70)
Salbutamol† 4.19 (3.81 to 4.61) 1.43 (1.34 to 1.53)
Prednisolone† 1.53 (1.38 to 1.69) 0.42 (0.32 to 0.52)
As this model was developed using case-control data, the intercept term is not applicable and has therefore not been presented.
The c statistic for this model in the external validation sample was 0.87 (95% CI 0.86 to 0.87).
*Estimated using a multivariable conditional logistic regression model.
†Within 3 years of COPD diagnosis or equivalent matched time point for controls.
Risk score=(former smoker×1.47)+(current smoker×2.48)+(unknown smoking status×1.05)+(asthma×0.64)+(1 episode of LRTI×0.59)+
(>1 episode of LRTI×0.80)+(1 episode of cough×0.35)+(>1 episode of cough×0.57)+(1 episode of dyspnoea×1.16)+(>1 episode of
dyspnoea×1.15)+(wheeze×0.62)+(sputum×0.40)+(unintended weight loss×0.56)+(1 antibiotic course×0.29)+(2 antibiotic course×0.43)+
(>2 antibiotic courses×0.59)+(salbutamol×1.43)+(prednisolone×0.42).
NB. Each variable can either take the value 0 (not present) or 1 (present).For example, A former smoker with a history of asthma who
presented with more than one lower respiratory tract infection and episode of cough in the past 3 years, reported of unintended weight loss
and received salbutamol and 2 course of antibiotics for a LRTI in the past 3 years would have the following risk score:
(1×1.47)+(0×2.48)+(0×1.05)+(1×0.64)+(0×0.59)+(1×0.80)+(0×0.35)+(1×0.57)+(0×1.16)+(0×1.15)+(0×0.62)+(0×0.40)+(1×0.56)+(0×0.29)
+(1×0.43)+(0×0.59)+(1×1.43)+(0×0.42)=5.9.
COPD, chronic obstructive pulmonary disease; LRTI, lower respiratory tract infection.
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ensure this clinical score will be widely applicable in
primary care in the UK and other similar health systems.
The score was also validated in a number of non-
randomly selected practices allowing for assessment of
the heterogeneity of its performance.
Weaknesses
Ideally we would like to have used previously undiag-
nosed COPD cases identiﬁed by case-ﬁnding/screening
to derive our risk score since their characteristics may
differ from incident cases identiﬁed clinically. We used a
coded diagnosis of COPD for our case deﬁnition.
However, there is good evidence that COPD is misdiag-
nosed and underdiagnosed in primary care,19 a propor-
tion of patients are likely to have undergone spirometry
of variable quality,20 and this may have led to some mis-
classiﬁcation of our cases and controls. Unfortunately
there was insufﬁcient spirometry data in our data set to
validate the diagnosis. Quint et al21 recently demon-
strated that clinical codes speciﬁc for COPD and emphy-
sema have a high PPV for validated COPD. We used
clinical codes for COPD that were recommended by the
GPRD (now CPRD) at the time of our analysis.
Although these largely overlapped with those recom-
mended by Quint et al they also included codes speciﬁc
for chronic bronchitis, which would not necessarily con-
stitute a diagnosis of COPD (although may increase the
likelihood of the development of airﬂow obstruction
and risk of mortality).22
The mean age of our study population (70 years) was
older than patients who would typically be targeted for
case ﬁnding. Age and sex, which are likely to be predic-
tors of COPD, could not be incorporated in the model
because of the matched case-control data. This also pre-
vented us from examining calibration performance in
the validation practices. Another limitation of the
matched case–control design is that c statistics are gener-
ally downwardly biased when estimated in such data.23 24
Therefore, it is possible the true c statistic may be closer
to 1 on application.
Some of the variables we explored, such as hospitalisa-
tions were poorly recorded, and may actually be signiﬁ-
cant predictors of COPD. In addition the absence of a
risk factor could be secondary to under-recording.
However, we aimed to produce a model that would be
implementable in a common primary care setting
drawing on routinely recorded data. If clinical coding
improves over time some of these variables may need to
be revisited as potential predictors and considered for
inclusion in future revised models. Finally, our clinical
score may not be applicable in health settings where
exposure to risk factors other than cigarette smoking
(eg, biomass fuels) is a signiﬁcant cause of COPD.
Implications for clinicians, policymakers and research
Our clinical score once further validated, could be used
by clinicians in primary care to stratify patients by risk of
COPD. This could be achieved primarily with the aid of
developed software applications that would automate the
calculations. Since the model was based entirely on rou-
tinely collected data it could also be integrated into
primary care clinical information systems to use data on
risk factors to stratify all eligible patients. Patients pre-
dicted to be at high risk of COPD could then be
referred for a clinical assessment including conﬁrmatory
spirometry testing.
However, further work is needed to validate or adapt
this preliminary model in other populations, notably in
Table 5 Characteristics of subjects in the external
validation sample (derived from 20 general practices)
Controls
(n=4196)
Cases
(n=2259)
N (%) N (%)
Mean age (SD) 69.8 (11.0) 70.0 (11.1)
Males 2110 (50.3) 1133 (50.2)
Socioeconomic quintile*
1 475 (11.3) 258 (11.4)
2 561 (13.4) 313 (13.9)
3 1072 (25.5) 574 (25.4)
4 308 (7.3) 159 (7.0)
5 1780 (42.4) 955 (42.3)
Smoking status
Never 1858 (44.3) 374 (16.6)
Former 799 (19.0) 674 (29.8)
Current 751 (17.9) 966 (42.8)
Missing 788 (18.8) 245 (10.8)
Body mass index
<18.5 1234 (29.4) 623 (27.6)
18.5–25 1098 (26.2) 643 (28.5)
25–30 1246 (29.7) 624 (27.6)
>30 618 (14.7) 369 (16.3)
*1=least deprived, 5=most deprived. Based on the Index of
Multiple Deprivation score of electoral ward,
Figure 1 Receiver under the operator characteristic (ROC)
curve for the test accuracy of the final risk score in the entire
external validation sample (c statistic=0.84, 95% CI 0.83 to
0.85), ignoring clustering of patients within practices. Each
point on the graph represents the performance (sensitivity and
specificity) of the risk score at specific thresholds.
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Figure 2 Random effects meta-analysis of the c statistics obtained for the final risk score when applied in each of the 20
validation practices separately. The summary result is the estimate of the average c statistic across the validation practices.
Table 6 Test accuracy of the final risk score in the external validation sample
Discrimination characteristics
Application of the score assuming 5.5% prevalence
of undiagnosed COPD
Score
threshold
Sensitivity
(%)
Specificity
(%)
Correctly
classified
(%) LR+ LR−
PPV
(%)
NPV
(%)
Screening
yield (%) NNS
Clinical
assessments per
case detected
0 100 0 35.0 1 – 5.5 – 5.50 19 19
0.5 96.1 34.7 56.2 1.47 0.11 7.9 99.3 5.29 19 13
1 90.6 51.9 65.5 1.88 0.18 9.9 99.0 4.98 21 11
1.5 89.4 55.1 67.1 1.99 0.19 10.4 98.9 4.92 21 10
2 81.2 71.9 75.2 2.89 0.26 14.4 98.5 4.47 23 7
2.5 63.2 87.4 79.0 5.02 0.42 22.6 97.6 3.48 29 5
3 55.8 91.9 79.3 6.89 0.48 28.6 97.3 3.07 33 4
3.5 47.6 94.6 78.1 8.80 0.55 33.9 96.9 2.62 39 3
4 40.4 95.8 76.4 9.57 0.62 35.8 96.5 2.22 45 3
4.5 23.2 98.3 72.0 13.5 0.78 44.0 95.6 1.28 79 3
5 20.6 98.4 71.2 13.1 0.81 44.3 95.5 1.13 89 3
5.5 11.3 99.5 68.6 21.5 0.89 55.8 95.1 0.62 161 2
6 5.53 99.7 66.7 18.9 0.95 50.9 94.8 0.30 329 2
6.5 3.23 99.8 65.0 19.4 0.97 52.5 94.7 0.18 563 2
Correctly classified= proportion of participants with disease status correctly classified.
LR, likelihood ratio (ie, the ratio by which the pretest probability is altered by a positive or negative test result);
NPV, negative predictive value (proportion of all participants with a negative test who are disease free);
NNS, number-needed-to-screen (the number of patients or patient records the risk score would need to be applied to) to identify one patient
with COPD; NPV, negative predictive value (proportion of all subjects with a negative test who are disease free); PPV, positive predictive
value (proportion of all participants with a positive test who have disease); Screening yield, proportion of all patients subjected to the risk
score who would be correctly identified as having COPD.
COPD, chronic obstructive pulmonary disease.
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case ﬁnding trials that have enrolled patients with previ-
ously undiagnosed COPD. This includes examining our
matching factors (age, sex and socioeconomic depriv-
ation) as potential predictors. The cost-effectiveness of
targeting patients at different thresholds should also be
evaluated. Future studies should also address the impact
of this tool on use and outcomes in general practice.
Conclusion
Our risk score shows promising accuracy and increased
efﬁciency over current methods for identifying patients
with COPD in primary care. Use of an externally vali-
dated score could be used for risk stratiﬁcation so that
high-risk patients can be efﬁciently identiﬁed and
referred for conﬁrmatory spirometry. However, evidence
that early identiﬁcation of COPD results in improved
patient outcomes must be robustly assessed before
screening for COPD can be recommended as part of
routine practice.
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